Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Gibson, Richard M ^a   Weber, Jan ^b   Winner, Dane ^a   Miller, Michael D ^c   Quiñones Mateu, Miguel E ^a,d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c GILEAD SCIENCES   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE; INTEGRASE INHIBITOR;

ANIMAL; ANTIVIRAL RESISTANCE; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPING TECHNIQUE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOUSE; MULTIDRUG RESISTANCE; MUTATION; PHENOTYPE; VIRAL TROPISM; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MICE; MUTATION; PHENOTYPE; VIRAL TROPISM; VIRUS REPLICATION;

EID: 84905841620     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104512     Document Type: Article

References (86)

1. Paredes R, Clotet B (2010) Clinical management of HIV-1 resistance. Antiviral Res 85: 245-265.
2. Zolopa AR (2010) The evolution of HIV treatment guidelines: current state-of-the-art of ART. Antiviral Res 85: 241-244.
3. Fast PE, Price MA, Rida WN, Kamali A, Karita E (2013) WHO's new guidelines for antiretroviral treatment. Lancet 382: 1778-1779.
4. Richardson ET, Grant PM, Zolopa AR (2013) Evolution of HIV treatment guidelines in high and low-income countries: Converging recommendations. Antiviral research.
5. Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, et al. (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. Journal of medicinal chemistry 51: 5843-5855.
6. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, et al. (2006) Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. JMedChem 49: 1506-1508. (Pubitemid 43376497)
7. Zolopa A, Gallant J, Cohen C, Sax P, Dejesus E, et al. (2012) Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients. Journal of the International AIDS Society 15: 18219.
8. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, et al. (2011) In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrobial Agents and Chemotherapy 55: 813-821.
9. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, et al. (2014) Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. The Journal of infectious diseases.
10. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, et al. (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet.
11. Lewin SR, Rouzioux C (2011) HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25: 885-897.
12. Archin NM, Margolis DM (2014) Emerging strategies to deplete the HIV reservoir. Current opinion in infectious diseases 27: 29-35.
13. Deeks SG (2003) Treatment of antiretroviral-drug-resistant HIV-1 infection. The Lancet 362: 2002-2011.
14. Tang JW, Pillay D (2004) Transmission of HIV-1 drug resistance. JClinVirol 30: 1-10. (Pubitemid 38457061)
15. Menendez-Arias L (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral research 98: 93-120.
16. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. JVirol 69: 5087-5094.
17. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
18. Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, et al. (1996) Basic concepts in RNA virus evolution. FASEB J 10: 859-864. (Pubitemid 26184164)
19. Eigen M (1993) Viral quasispecies. SciAm 269: 42-49.
20. Domingo E, Menendez-Arias L, Quinones-Mateu ME, Holguin A, Gutierrez-Rivas M, et al. (1997) Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. ProgDrug Res 48: 99-128. (Pubitemid 27242826)
21. Quinones-Mateu ME, Arts EJ (2001) HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F et al., editors. HIV Sequence Compendium 2001. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory. pp. 134-170.
22. Quinones-Mateu ME, Arts EJ (2006) Virus fitness: concept, quantification, and application to HIV population dynamics. Current Topics in Microbiology and Immunology 299: 83-140. (Pubitemid 43086562)
23. Preston BD, Dougherty JP (1996) Mechanisms of retroviral mutation. Trends in Microbiology 4: 16-21. (Pubitemid 26028016)
24. Quinones-Mateu ME, Arts EJ (2002) Fitness of drug resistant HIV-1: methodology and clinical implications. Drug ResistUpdat 5: 224-233. (Pubitemid 36132804)
25. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, et al. (1993) Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365: 671-673.
26. Church JD, Jones D, Flys T, Hoover D, Marlowe N, et al. (2006) Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. The Journal of molecular diagnostics: JMD 8: 430-432; quiz 527.
27. Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, et al. (2006) Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. Journal of clinical microbiology 44: 2612-2614. (Pubitemid 44092442)
28. Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, et al. (1993) Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 15: 120-127. (Pubitemid 23202530)
29. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, et al. (2003) Accuracy of the TRUGENE HIV-1 genotyping kit. Journal of clinical microbiology 41: 1586-1593. (Pubitemid 36428108)
30. Li JZ, Kuritzkes DR (2013) Clinical implications of HIV-1 minority variants. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 56: 1667-1674.
31. Gianella S, Richman DD (2010) Minority variants of drug-resistant HIV. The Journal of infectious diseases 202: 657-666.
32. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA: the journal of the American Medical Association 305: 1327-1335.
33. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. (2011) Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 53: 732-742.
34. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. (2011) Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. The Journal of infectious diseases 203: 237-245.
35. Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, et al. (2011) Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 25: 325-333.
36. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, et al. (2010) Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. The Journal of infectious diseases 201: 662-671.
37. Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, et al. (2006) Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20: 701-710. (Pubitemid 43884297)
38. Lalonde MS, Troyer RM, Syed AR, Bulime S, Demers K, et al. (2007) Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. JClinMicrobiol 45: 2604-2615. (Pubitemid 47295494)
39. Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, et al. (2011) Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PloS one 6: e28952.
40. Avidor B, Girshengorn S, Matus N, Talio H, Achsanov S, et al. (2013) Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. Journal of clinical microbiology 51: 880-886.
41. Chang MW, Oliveira G, Yuan J, Okulicz JF, Levy S, et al. (2013) Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. Journal of Virological Methods 189: 232-234.
42. Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, et al. (2012) Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PloS one 7: e36494.
43. Gibson RM, Meyer AM, Winner D, Archer J, Feyertag F, et al. (2014) Sensitive Deep Sequencing-based HIV-1 Genotyping Assay to Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as well as HIV-1 Coreceptor Tropism. Antimicrobial Agents and Chemotherapy 58: 2167-2185.
44. Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, et al. (2013) Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. The Journal of infectious diseases 207: 893-897.
45. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, et al. (2012) Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 26: 185-192.
46. Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, et al. (2011) Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PloS one 6: e19461.
47. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, et al. (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. JInfectDis 201: 814-822.
48. McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, et al. (2007) Resistance and cross resistance to fist generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antiviral Therapy 12: S11.
49. Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, et al. (2011) Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 39Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrobial Agents and Chemotherapy 55: 3729-3742.
50. Quinones-Mateu ME, Domingo E (1999) Nucleotide diversity in three different genomic regions of Venezuelan HIV type 1 isolates: a subtyping update. AIDS ResHumRetroviruses 15: 73-79. (Pubitemid 29038328)
51. Weber J, Quinones-Mateu ME (2007) Novel anti-HIV-1 screening system based on intact recombinant viruses expressing synthetic firefly and renilla luminescent proteins. AntivirTher 12: S155.
52. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. AmJHyg 27 493-497.
53. Holland AU, Munk C, Lucero GR, Nguyen LD, Landau NR (2004) Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. Virology 319: 343-352. (Pubitemid 38251274)
54. Weber J, Vazquez AC, Winner D, Gibson RM, Rhea AM, et al. (2013) Sensitive Cell-based Assay to Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism. Journal of clinical microbiology 51: 1517-1527.
55. Weber J, Rose JD, Vazquez AC, Winner D, Margot N, et al. (2013) Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors. PloS one 8: e65631.
56. Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, et al. (2000) A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. JVirol 74: 9222-9233.
57. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2013) Update of the drug resistance mutations in HIV-1: March 2013. Topics in antiviral medicine 21: 6-14.
58. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947-2948. (Pubitemid 350162903)
59. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Molecular biology and evolution 28: 2731-2739.
60. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, et al. (2007) Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. AntivirTher 12: 1097-1106. (Pubitemid 350114990)
61. Harrigan PR (2009) MOTIVATE tropism study group. Optimization of clinical cutoffs for determining HIV co-receptor use by population and "deep" sequencing methods. Infectious Diseases Society of America Philadelphia, PA.
62. Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, et al. (2011) Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS pathogens 7: e1002106.
63. Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ (2007) Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. Journal of Virology 81: 8258-8269. (Pubitemid 47101511)
64. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome research 17: 1195-1201. (Pubitemid 47204863)
65. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. (2009) Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. The Journal of infectious diseases 199: 693-701.
66. Messiaen P, Verhofstede C, Vandenbroucke I, Dinakis S, Van Eygen V, et al. (2012) Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology 426: 7-11.
67. Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, et al. (2012) Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PloS one 7: e30118.
68. D'Aquila RT, Geretti AM, Horton JH, Rouse E, Kheshti A, et al. (2011) Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing. AIDS Research and Human Retroviruses 27: 201-209.
69. Recordon-Pinson P, Papuchon J, Reigadas S, Deshpande A, Fleury H (2012) K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data. PloS one 7: e36549.
70. Vandenhende MA, Bellecave P, Recordon-Pinson P, Reigadas S, Bidet Y, et al. (2014) Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure. PloS one 9: e86771.
71. McColl DJ, Chen X (2010) Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral research 85: 101-118.
72. Dunne AL, Mitchell FM, Coberly SK, Hellmann NS, Hoy J, et al. (2001) Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 15: 1471-1475. (Pubitemid 32744593)
73. Ji H, Masse N, Tyler S, Liang B, Li Y, et al. (2010) HIV drug resistance surveillance using pooled pyrosequencing. PloS one 5: e9263.
74. Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, et al. (2008) Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. Journal of Virology 82: 10747-10755. (Pubitemid 352691166)
75. Bellecave P, Recordon-Pinson P, Papuchon J, Vandenhende MA, Reigadas S, et al. (2013) Detection of Low-Frequency HIV Type 1 Reverse Transcriptase Drug Resistance Mutations by Ultradeep Sequencing in Naive HIV Type 1-Infected individuals. AIDS Research and Human Retroviruses.
76. Gonzalez S, Tully DC, Gondwe C, Wood C (2013) Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing. Current HIV research 11: 43-49.
77. Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, et al. (2009) Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PloS one 4: e6079.
78. De Wolf H, Van Marck H, Mostmans W, Thys K, Vandenbroucke I, et al. (2011) HIV-1 nucleotide mixture detection in the virco((R))TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing. Journal of Virological Methods 175: 129-132.
79. Lee GQ, Swenson LC, Poon AF, Martin JN, Hatano H, et al. (2012) Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencing. PloS one 7: e46181.
80. Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, et al. (2012) Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. Journal of Virology 86: 6231-6237.
81. Dudley DM, Gao Y, Nelson KN, Henry KR, Nankya I, et al. (2009) A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques 46: 458-467.
82. Weber J, Rangel HR, Chakraborty B, Tadele M, Martinez MA, et al. (2003) A Novel TaqMan Real-Time PCR Assay to Estimate ex vivo Human Immunodeficiency Virus type 1 Fitness in the Era of Multi-Target (pol and env) Antiretroviral Therapy. Journal of General Virology 84: 2217-2228. (Pubitemid 36927253)
83. Weber J, Weberova J, Carobene M, Mirza M, Martinez-Picado J, et al. (2006) Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods 136: 102-117. (Pubitemid 44051582)
84. Ibanez A, Clotet B, Martinez MA (2000) Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. The Journal of general virology 81: 85-95. (Pubitemid 30047909)
85. Kitrinos KM, Nelson JA, Resch W, Swanstrom R (2005) Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. Journal of Virology 79: 10627-10637. (Pubitemid 41098602)
86. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW (2011) HIV-1 integrase inhibitor resistance and its clinical implications. The Journal of infectious diseases 203: 1204-1214.